Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 50090-4737

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-4737). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

The text describes a graph or chart, labeled Figure 1, which shows the percentage reduction in CPS rate for patients given Divalproex Sodium Delayed-Release Tablets as compared to patients given a placebo. The graph shows that half of the patients showed improvement while the other half showed either no change or worsening.*

FDA Label Image

Figure 2 (Divalproex Fig2)

The text describes a figure (Figure 2) showing the reduction in CPS rate for high and low doses of Divalproex Sodium delayed-release tablets. The figure shows a graph with three categories: improvement, no change, and worsening, and represents 50% of patients.*

FDA Label Image

Figure-3 (Divalproex Fig3)

This appears to be a mix of numerical values and medication names. The values 12, 0.6, and 12t are present, along with a strange text string "[riacebo" and the value "*p=0.006". The medication name "Divalproex Sodium Extended-Release Tablets" is also present. It is unclear how these elements relate to each other or what the overall context is.*

FDA Label Image

Structure (Divalproex Str)

FDA Label Image

Label Image (Lbl500904737)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.